Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Mutant selectivity and combinations of a phosphoinositide 3-kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer

Mutant selectivity and combinations of a phosphoinositide 3-kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer

US Patent 9107926 · Granted Aug 18, 2015

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhib2023
Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhib2022
Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhib2021
Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhib2021
Combination of Bcl-2 inhibitor and MEK inhibitor for the treatment of cancer2021
Combination therapy with an anti-HER2 antibody-drug conjugate and a Bcl-2 inhibi2021
Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods2018
Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods2018
Methods of treating PR-positive, luminal A breast cancer with PI3K inhibitor, pi2018
Methods and compositions for modulating estrogen receptor mutants2018
Methods and compositions for modulating estrogen receptor mutants2018
Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods2017